CL2017002680A1 - Construcciones de calicheamicina y sus métodos de uso - Google Patents
Construcciones de calicheamicina y sus métodos de usoInfo
- Publication number
- CL2017002680A1 CL2017002680A1 CL2017002680A CL2017002680A CL2017002680A1 CL 2017002680 A1 CL2017002680 A1 CL 2017002680A1 CL 2017002680 A CL2017002680 A CL 2017002680A CL 2017002680 A CL2017002680 A CL 2017002680A CL 2017002680 A1 CL2017002680 A1 CL 2017002680A1
- Authority
- CL
- Chile
- Prior art keywords
- calicheamycin
- methods
- constructions
- conjugates
- adc
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Se proveen conjugados de fármaco y anticuerpo (ADC) que comprenden calicheamicina y métodos de uso de los mismos para el tratamiento de trastornos proliferativos.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562150693P | 2015-04-21 | 2015-04-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002680A1 true CL2017002680A1 (es) | 2018-04-27 |
Family
ID=57144229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002680A CL2017002680A1 (es) | 2015-04-21 | 2017-10-20 | Construcciones de calicheamicina y sus métodos de uso |
Country Status (20)
Country | Link |
---|---|
US (1) | US20180133337A1 (es) |
EP (1) | EP3285807A4 (es) |
JP (1) | JP2018515457A (es) |
KR (1) | KR20170139110A (es) |
CN (1) | CN107849146A (es) |
AR (1) | AR104333A1 (es) |
AU (1) | AU2016250537A1 (es) |
BR (1) | BR112017022682A2 (es) |
CA (1) | CA2983158A1 (es) |
CL (1) | CL2017002680A1 (es) |
CO (1) | CO2017010692A2 (es) |
EA (1) | EA201792312A1 (es) |
HK (1) | HK1246194A1 (es) |
IL (1) | IL255161A0 (es) |
MA (1) | MA41959A (es) |
PE (1) | PE20180599A1 (es) |
PH (1) | PH12017501930A1 (es) |
SG (1) | SG11201708629VA (es) |
TW (1) | TW201713363A (es) |
WO (1) | WO2016172273A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3621658A1 (en) * | 2017-05-10 | 2020-03-18 | Sanofi | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation |
WO2019110725A1 (en) | 2017-12-06 | 2019-06-13 | Synaffix B.V. | Enediyne conjugates |
DK3710485T3 (da) | 2018-05-30 | 2021-05-10 | Abbvie Stemcentrx Llc | Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder |
EP3927347B1 (en) * | 2019-02-18 | 2023-12-27 | Medivir Aktiebolag | Drug combination for use in a method of treating liver cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US6576746B2 (en) * | 1998-10-13 | 2003-06-10 | Immunomedics, Inc. | Site-specific labeling of disulfide-containing targeting vectors |
EP1507556B1 (en) * | 2002-05-02 | 2016-07-27 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
US8815226B2 (en) * | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
WO2014107024A1 (ko) * | 2013-01-03 | 2014-07-10 | 셀트리온 | 항체-링커-약물 결합체, 그의 제조방법 및 그를 포함하는 항암제 조성물 |
CN105848671B (zh) * | 2013-08-28 | 2019-12-13 | 艾伯维施特姆森特克斯有限责任公司 | 位点特异性抗体缀合方法和组合物 |
-
2016
- 2016-04-21 TW TW105112526A patent/TW201713363A/zh unknown
- 2016-04-21 US US15/567,904 patent/US20180133337A1/en not_active Abandoned
- 2016-04-21 EP EP16783812.7A patent/EP3285807A4/en not_active Withdrawn
- 2016-04-21 EA EA201792312A patent/EA201792312A1/ru unknown
- 2016-04-21 PE PE2017002310A patent/PE20180599A1/es not_active Application Discontinuation
- 2016-04-21 SG SG11201708629VA patent/SG11201708629VA/en unknown
- 2016-04-21 CA CA2983158A patent/CA2983158A1/en not_active Abandoned
- 2016-04-21 AR ARP160101092A patent/AR104333A1/es unknown
- 2016-04-21 CN CN201680036382.0A patent/CN107849146A/zh active Pending
- 2016-04-21 MA MA041959A patent/MA41959A/fr unknown
- 2016-04-21 JP JP2017555554A patent/JP2018515457A/ja active Pending
- 2016-04-21 KR KR1020177033533A patent/KR20170139110A/ko unknown
- 2016-04-21 BR BR112017022682A patent/BR112017022682A2/pt not_active Application Discontinuation
- 2016-04-21 AU AU2016250537A patent/AU2016250537A1/en not_active Abandoned
- 2016-04-21 WO PCT/US2016/028530 patent/WO2016172273A1/en active Application Filing
-
2017
- 2017-10-19 CO CONC2017/0010692A patent/CO2017010692A2/es unknown
- 2017-10-20 IL IL255161A patent/IL255161A0/en unknown
- 2017-10-20 PH PH12017501930A patent/PH12017501930A1/en unknown
- 2017-10-20 CL CL2017002680A patent/CL2017002680A1/es unknown
-
2018
- 2018-05-04 HK HK18105790.1A patent/HK1246194A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
TW201713363A (zh) | 2017-04-16 |
PE20180599A1 (es) | 2018-04-09 |
CN107849146A (zh) | 2018-03-27 |
HK1246194A1 (zh) | 2018-09-07 |
AU2016250537A1 (en) | 2018-11-08 |
KR20170139110A (ko) | 2017-12-18 |
CO2017010692A2 (es) | 2018-01-31 |
IL255161A0 (en) | 2017-12-31 |
BR112017022682A2 (pt) | 2018-07-10 |
JP2018515457A (ja) | 2018-06-14 |
AR104333A1 (es) | 2017-07-12 |
US20180133337A1 (en) | 2018-05-17 |
MA41959A (fr) | 2018-02-28 |
EP3285807A4 (en) | 2018-12-26 |
CA2983158A1 (en) | 2016-10-27 |
EA201792312A1 (ru) | 2018-06-29 |
SG11201708629VA (en) | 2017-11-29 |
PH12017501930A1 (en) | 2018-03-19 |
EP3285807A1 (en) | 2018-02-28 |
WO2016172273A1 (en) | 2016-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
CL2019000334A1 (es) | Nuevos conjugados de anticuerpo y usos de los mismos (divisional solicitud 201502357) | |
CL2017002422A1 (es) | Derivados de maitansinoide, conjugados de los mismos, y métodos de uso. | |
CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
ECSP18049762A (es) | Nuevos anticuerpos anti-claudina y sus métodos de uso | |
CL2017003240A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
CR20180013A (es) | Anticuerpos anti-tau y métodos de uso. | |
CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
CL2017002150A1 (es) | Receptores de antígeno quiméricos anti-dll3 y métodos de uso | |
CL2017001408A1 (es) | Anticuerpos anti-cd79b y métodos de uso | |
CL2017001289A1 (es) | Compuestos bicíclicos fusionados, sus composiciones y su uso para el tratamiento de enfermedades relacionadas con la modulación del receptor x farnesoide (fxr). | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
DOP2015000219A (es) | Compuestos de heteroarilo y sus usos | |
CR20170240A (es) | Anticuerpos anti-interleucina-33 y sus usos | |
CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
CR20160362A (es) | Anticuerpos anti-jagged1 y metodos de uso | |
PE20160870A1 (es) | Anticuerpos anti-claudina novedosos y metodos de uso | |
CR20190271A (es) | Anticuerpos antitau y métodos de uso | |
CL2016001743A1 (es) | Conjugados de anticuerpo-fármaco (adc) de duocarmicina para su uso en el tratamiento de cáncer de endometrio. | |
PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
CR20150549A (es) | Compuestos heterocíclicos y sus usos | |
CL2017001661A1 (es) | Compuestos biciclicos fusionados para el tratamiento de una enfermedad. | |
CR20160270A (es) | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN | |
ECSP17031725A (es) | Receptores quiméricos de anitígeno anti-clon y métodos de uso | |
CL2018001139A1 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos. |